EP3322731
AÐFERÐ VIÐ AÐ MEÐHÖNDLA KRABBAMEIN MEÐ ÓNÆMISÖRVANDI LYFI; MÓTEFNI SEM BINST VIÐ STÝRÐAN FRUMUDAUÐA-1 VIÐTAKA (PD-1) EÐA STÝRÐAN FRUMUDAUÐA BINDIL 1 (PD-L1)
:
EP einkaleyfi í gildi á Íslandi:
14.7.2016:
13.1.2021:
16744626.9
:
10.3.2021:
15.4.2021
:
13.7.2036:
13.7.2026:
31.7.2026
:
METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)
14.7.2016
13.1.2021
10.3.2021
15.4.2021
13.7.2026
:
Bristol-Myers Squibb Company:
Route 206 and Province Line Road, Princeton, NJ 08543, US
:
MANEKAS, Demetrios:
Howell, New Jersey 07731, US
:
GROSSO, Joseph:
Princeton, New Jersey 08543, US
:
ANDERSON, Jeffrey:
Princeton, New Jersey 08543, US
:
G.H. Sigurgeirsson ehf.:
Borgartúni 26, 105, Reykjavík,
:
201562192396 P:
14.7.2015:
US
:
US2016042297:
14.7.2016
:
C07K 16/28, A61K 39/395, G01N 33/574, C12Q 1/6886, A61K 39/00, A61P 35/00, C12Q 1/70
: 6
: 8.6.2021
: 13.7.2022
: Árnason Faktor ehf.
: 7
: 9.6.2022
: 13.7.2023
: Árnason Faktor ehf.
: 8
: 11.6.2023
: 13.7.2024
: Árnason Faktor ehf.
: 9
: 6.6.2024
: 13.7.2025
: Árnason Faktor ehf.
: 10
: 7.7.2025
: 13.7.2026
: Árnason Faktor ehf.